first line
Recently Published Documents


TOTAL DOCUMENTS

27946
(FIVE YEARS 9377)

H-INDEX

206
(FIVE YEARS 36)

2022 ◽  
Vol 28 ◽  
pp. 67-75
Author(s):  
Shereef Elsamany ◽  
Gihan Hamdy Elsisi ◽  
Fayza Ahmed Mohamed Hassanin ◽  
Khaldoon Saleh ◽  
Emad Tashkandi

2022 ◽  
Vol 12 (4) ◽  
pp. 690-694
Author(s):  
Wei Zhang ◽  
Yi Chen ◽  
Bin Wang ◽  
Xueren Feng ◽  
Lijuan Zhang ◽  
...  

Lung cancer is a worldwide issue which account for the death of thousands every year. Paclitaxel (PTX) as the first line chemotherapy drug to treat lung cancer, its clinical applications is largely limited by its poor solubility. The facile preparation of pharmaceutical formulations to increase the solubility as well as targetability of PTX is of vital importance in lung cancer treatment. Herein, we introduced a facile method to prepare PTX nano-suspensions (NSs), which have high drug loading as well as well-dispersed particle size. The in vitro cell experiments revealed its capability to enhance the drug accumulation in A549 cells than free PTX. Moreover, in vivo animal assay suggested its better tumor accumulation and antitumor efficacy than PTX injection (Taxol).


AIDS ◽  
2022 ◽  
Vol 36 (2) ◽  
pp. 317-318
Author(s):  
Juan V. Guanira ◽  
Carl J. Fichtenbaum
Keyword(s):  

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
John Sharp ◽  
Vinay Prasad

Abstract Importance It is unknown whether and to what degree trials submitted to the US FDA to support drug approval adhere to NCCN guideline-recommended care in their baseline and surveillance CNS imaging protocols. Objective We sought to characterize the frequency with which the trials cited in US FDA drug approvals for first line advanced NSCLC between 2015 and 2020 deviated from NCCN guideline-recommended care for baseline and surveillance CNS imaging. Design, setting, and participants Retrospective observational analysis using publicly available data of (1) list of trials cited by the FDA in drug approvals for first line advanced NSCLC from 2015 to 2020 (2) individual trial protocols (3) published trial data and supplementary appendices (4) archived versions of the NCCN guidelines for NSCLC from 2009 to 2018 (the years during which the trials were enrolling). Main outcomes and measures Estimated percentage of trials for first line advanced NSCLC leading to FDA approval which deviated from NCCN guideline-recommended care with regards to CNS baseline and surveillance imaging. Results A total of 14 studies that had been cited in FDA drug approvals for first line advanced NSCLC met our inclusion criteria between January 1, 2015 and September 30, 2020. Of these trials, 8 (57.1%) deviated from NCCN guidelines in their baseline CNS imaging requirement. The frequency of re-assessment of CNS disease was variable amongst trials as well, with 9 (64.3%) deviating from NCCN recommendations. Conclusions and relevance The trials supporting US FDA drug approvals in first line advanced NSCLC often have CNS imaging requirements that do not adhere to NCCN guidelines. Many trials permit alternative, substandard methods and the proportion of patients undergoing each modality is uniformly not reported. Nonstandard CNS surveillance protocols are common. To best serve patients with advanced NSCLC in the US, drug approvals by the FDA must be based on trials that mirror clinical practice and have imaging requirements consistent with current US standard of care.


Sign in / Sign up

Export Citation Format

Share Document